PBAC's latest decision on Aprepitant: Recommended (2019). Considered for Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic and moderately emetogenic cancer chemotherapy, and prevention of postoperative nausea and vomiting.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
4
first 2006
Submissions
4
2006 → 2019
Eligible population
Patients requiring prevention of acute and delayed nausea and vomiting associated with highly emetogenic or moderately emetogenic cancer chemotherapy, and patients requiring prevention of postoperative nausea and vomiting.
Therapy area
Oncology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
Cost-minimisation
ICER note
Cost-minimisation submission; no economic model or ICER calculated.
Submission history
Mar 2006: Recommended with restriction · Authority Required
Nov 2015: Not recommended · Restricted
Mar 2016: Recommended with restriction · Authority Required